BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT)
| Market Cap | 275.57M-71.4% |
| Revenue (ttm) | 0 |
| Net Income | -182.11M-108.1% |
| EPS | -2.27+34.2% |
| Shares Out | 80.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 321,309 |
| Open | 3.46 |
| Previous Close | 3.50 |
| Day's Range | 3.42 - 3.57 |
| 52-Week Range | 3.36 - 14.87 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | 19.00(+452.33%) |
| Earnings Date | Nov 11, 2026 |
Insiders here have filed 6 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About BBOT
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
$BBOT stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in BBOT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BBOT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BBOT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New BBOT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BBOT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BBOT
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $12.52M |
| VXFVanguard Extended Market ETF | $4.91M |
| XBIState Street SPDR S&P Biotech ETF | $2.41M |
| IBBiShares Biotechnology ETF | $1.27M |
| SCHASchwab U.S. Small-Cap ETF | $780.85K |
| BBCVirtus Biotech Clinical Trials ETF | $143.31K |
Estimated from each fund’s disclosed top holdings × AUM
BBOT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BBOT’s recent data — informational, not investment advice